Evidence record 2907 · automatically gathered

China’s drug industry pivots to AI-powered candidates to drive next wave of deals

After China’s cross-border deals for innovative drugs hit a record US$110 billion in the first half of 2026, the sector is now pivoting towards artificial intelligence-powered candidates to drive the next wave of transactions. China accounted for about 30 per cent of all new drugs currently under development worldwide, ranking second globally, according to Lan Gongtao, deputy director general of the Department of Drug Registration at the National Medical Products Administration. China’s...

Record details

Published: 13 July 2026
Source: SCMP Tech (HK/CN)
Category: News
Topics: Healthcare
Retrieved: 14 July 2026

source-onlyevidence status

These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.

How to cite this record

ethics.ai (13 July 2026), “China’s drug industry pivots to AI-powered candidates to drive next wave of deals,” evidence record 2907, https://ethics.ai/record/2907 (originally published by SCMP Tech (HK/CN)).

JSON

Use and limitations

This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.